Inozyme Pharma (INZY)
NASDAQ:INZY
US Market
Holding INZY?
Track your performance easily

Inozyme Pharma (INZY) Financial Statements

673 Followers

Inozyme Pharma Financial Overview

Inozyme Pharma's market cap is currently ―. The company's EPS TTM is $-1.456; its P/E ratio is -3.99; Inozyme Pharma is scheduled to report earnings on November 5, 2024, and the estimated EPS forecast is $-0.44. See an overview of income statement, balance sheet, and cash flow financials.
Jun 24Mar 24Dec 23Sep 23Jun 23
Income Statement-
Total Revenue-----
Gross Profit-----
EBIT$ -25.64M$ -22.02M$ -15.00M$ -16.64M$ -15.58M
EBITDA$ -23.03M$ -21.84M$ -14.79M$ -17.73M$ -16.32M
Net Income Common Stockholders$ -27.03M$ -23.35M$ -21.54M$ -16.64M$ -15.58M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 144.52M$ 166.15M$ 188.59M$ 192.44M$ 140.25M
Total Assets$ 155.71M$ 176.94M$ 200.85M$ 205.70M$ 150.93M
Total Debt$ 46.71M$ 46.63M$ 46.59M$ 34.10M$ 34.12M
Net Debt$ -97.81M$ -119.52M$ -142.00M$ -158.34M$ -106.13M
Total Liabilities$ 61.29M$ 58.11M$ 60.37M$ 45.49M$ 45.34M
Stockholders Equity$ 94.43M$ 118.81M$ 140.48M$ 160.21M$ 105.64M
Cash Flow-
Free Cash Flow$ -23.66M$ -24.57M$ -18.59M$ -18.88M$ -15.56M
Operating Cash Flow$ -23.66M$ -24.53M$ -18.49M$ -18.87M$ -15.55M
Investing Cash Flow$ 17.82M$ 10.39M$ -6.47M$ -44.62M$ -16.33M
Financing Cash Flow$ 458.00K$ 159.00K$ 12.52M$ 69.72M$ 23.64M
Currency in USD

Inozyme Pharma Earnings and Revenue History

Inozyme Pharma Debt to Assets

Inozyme Pharma Cash Flow

Inozyme Pharma Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis